A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocol.
Gribaleva E, Krogh NS, Prieto-Merino D, Coker B, Jackson A, Akkoc A, Birkner T, Bruninx E, Hennessy C, Chan K, Cutlar L, Farrell B, Fletcher G, Gerbens L, Frostrup AG, Henrohn D, Hyseni A, Irvine AD, Malek R, McCarthy C, Vittrup I, Ouwerkerk W, Randall R, Spuls PI, Thomsen SF, Wall D, Weidinger S, Werfel T, Schmitt J, Flohr C.
Gribaleva E, et al. Among authors: mccarthy c.
Skin Health Dis. 2025 Apr 22;5(3):196-202. doi: 10.1093/skinhd/vzaf020. eCollection 2025 Jun.
Skin Health Dis. 2025.
PMID: 40584946
Free PMC article.